ZVRA
Zevra Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +7.5% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 72 | +5 | 28.98M | $414.85M | +11 | −6 |
| Q1 2026 | 69 | 0 | 26.10M | $242.75M | +4 | −4 |
| Q4 2025 | 68 | +1 | 25.36M | $227.23M | +1 | n/a |
| Q3 2025 | 16 | +2 | 19.14M | $181.99M | +2 | n/a |
| Q2 2025 | 11 | 0 | 17.09M | $150.53M | n/a | n/a |
| Q1 2025 | 8 | 0 | 6.58M | $49.25M | +1 | −1 |
| Q4 2024 | 8 | +1 | 6.30M | $52.58M | +2 | −1 |
| Q3 2024 | 6 | +2 | 1.92M | $13.36M | +3 | −1 |
| Q2 2024 | 4 | n/a | 1.15M | $5.62M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 4.17M | +15.2% | $36.72M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 2 | BlackRock ✦ (passive) | 4.08M | n/a | $35.96M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 3 | The Vanguard Group ✦ (passive) | 2.95M | n/a | $26.01M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 4 | Fidelity (FMR) ✦ | 2.29M | n/a | $20.17M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 5 | Geode Capital Management ✦ (passive) | 1.24M | +0.8% | $10.95M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 6 | State Street Global Advisors ✦ (passive) | 1.24M | +5.5% | $10.94M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Millennium Management ✦ | 634.82K | +484.0% | $5.59M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | D. E. Shaw & Co. ✦ | 189.31K | +591.7% | $1.67M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 9 | Wellington Management ✦ | 146.28K | +4.2% | $1.29M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 10 | Citadel Advisors ✦ | 114.27K | -54.1% | $1.01M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 11 | T. Rowe Price ✦ | 25.69K | +13.2% | $227,000 | 0.0% | ▲ Add | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 147 holders, 40.93M shares, $378.34M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 20.00K sh · $224,948
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology